Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Trade Show, Webcast

Agilent Announces New Mass Spectrometry Products at ASMS 2020 Reboot


Agilent Technologies Inc. (NYSE: A) today announced two new mass spectrometry (MS) products: the Agilent 6470B Triple Quadrupole LC/MS (6470 LC/TQ) system, and the Agilent RapidFire 400 system. Both deliver even faster detection of target compounds providing customers increased sample throughput and reduced time to generate results. The instruments are being introduced at ASMS 2020 Reboot, the interactive, online version of the annual conference of the American Society for Mass Spectrometry, being held June 1-12, 2020.

"Agilent continues to strive to meet the evolving needs of our mass spec customers, and address the challenges they face daily," said Monty Benefiel, vice president, and general manager of Agilent's Mass Spectrometry Division. "These new products offer customers workflow solutions that maximize sample throughput and stability, as well as greater reliability than ever before."

The 6470B system includes enhancements that boost system uptime and improve overall system performance for low-level detection in routine, high-throughput environments. Customers running a single chromatographic method for applications such as multi-residue screening will see greater data fidelity, reproducibility, and sensitivity. The system integrates seamlessly into existing analytical labs and customer workflows?and it offers quicker routine maintenance through the addition of VacShield technology, designed to easily remove ion injectors without venting.

The high-throughput RapidFire 400 integrated autosampler provides fast results with cycle times as short as 2 sec/sample and adds optional sample cooling for greater sample stability. The system includes barcode reading capabilities for sample tracking, now supports 1,536 well plates, and allows unattended operation for the analysis of more than 98,000 samples. It is further designed to integrate with the Ultivo LC/TQ system, further reducing lab space requirements.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.


These press releases may also interest you

at 01:00
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. ? ?  Q1 2024? Q1 2023? % change? ?m? ?m? ActualCER1Growth...

23 avr 2024
GenScript, a global leader in life sciences and biotechnology, successfully hosted an Open Day event at its Singapore facility on the 16th of April, welcoming more than 50 representatives from Singapore. This event provided an exclusive look into...

23 avr 2024
Cybervation, an award-winning global technology and healthcare solutions company, proudly announces that its CEO, Purba Majumder, has been distinguished as one of the 2024 100 Women to KNOW Across America. This award from KNOW Women recognizes...

23 avr 2024
The report titled "Glycated Albumin Assay Market by Product (Animal Glycated Albumin Assay, Human Glycated Albumin Assay), Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User - Global Forecast 2024-2030" is now available on...

23 avr 2024
The report titled "Health & Wellness Food Market by Type (Fresh & Natural, Functional Foods & Beverages, Heat & Eat), Nature (Genetically Modified Organism Food, Non-Genetically Modified Organism Food), Fat Content, Category, Free From Category,...

23 avr 2024
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...



News published on and distributed by: